Change Language

Select Language

COVID-19
The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.

Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032

The Non-Small Cell Lung Cancer (NSCLC) Market has been comprehensively analyzed in IMARC’s new report titled “Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast”. Non-small cell lung cancer (NSCLC) is a form of oncology disease in which malignant (cancer) cells form in the lung tissues. It can be categorized into squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Other less-known types of non-small cell lung cancer are adenosquamous carcinoma, sarcomatoid carcinoma, salivary gland carcinoma, carcinoid tumor, and unclassified carcinoma. The major symptoms of non-small lung cancer are continuous cough and shortness of breath. In addition to this, chest discomfort or pain, wheezing, blood in sputum, hoarseness, loss of appetite, weight loss, tiredness, and trouble swallowing are the other common symptoms experienced by patients suffering from non-small cell lung cancer (NSCLC). Non-small cell lung cancer is diagnosed and staged using pulmonary examination tests, which are carried out simultaneously. Physical exams, laboratory tests, chest X-rays, CT scans (CAT scans), sputum cytology, and thoracentesis are the common tests and procedures performed to detect non-small cell lung cancer (NSCLC) among patients. Some treatment options for non-small cell lung cancer (NSCLC) are bronchoscopy, thoracoscopy, mediastinoscopy, lymph node biopsy, etc.

The increasing incidences of respiratory disorders on account of the deteriorating air quality, unhealthy lifestyle preferences, and high smoking rates among the masses are primarily driving the non-small cell lung cancer market. In addition to this, the expanding geriatric population, who are more prone to develop acute respiratory illnesses, is also bolstering the market growth. Moreover, the rising demand for targeted therapies owing to improved patient outcomes is further creating a positive outlook for the market. These treatments aim to selectively target cancer cells by adhering to or obstructing targets that are present on their surfaces. Besides this, the widespread adoption of radiation therapy combined with chemotherapy to treat patients with locally advanced unresectable disease is also acting as a significant growth-inducing factor. Several other factors, including the continuous upgradation of the existing healthcare infrastructures and the introduction of advanced variants with enhanced efficacy and effectiveness of treatment, are expected to drive the non-small cell lung cancer market in the coming years.

IMARC Group’s new report "Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Non-Small Cell Lung Cancer (NSCLC) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Non-Small Cell Lung Cancer (NSCLC) market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Non-Small Cell Lung Cancer (NSCLC) across the seven major markets. According to the report the United States has the largest patient pool for Non-Small Cell Lung Cancer (NSCLC) and also represents the largest market for Non-Small Cell Lung Cancer (NSCLC) treatment. Furthermore, the current Non-Small Cell Lung Cancer (NSCLC) treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Non-Small Cell Lung Cancer (NSCLC) market in any manner.

Time Period of the Study

  • Base Year: 2021
  • Historical Period: 2017-2021
  • Market Forecast: 2022-2032
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, Current and Future Epidemiology Scenario
  • Historical, Current and Future Performance of the Non-Small Cell Lung Cancer (NSCLC) Market
  • Historical, Current and Future Performance of Various Therapeutic Categories in the Non-Small Cell Lung Cancer (NSCLC) Market
  • Sales of Various Drugs Across the Non-Small Cell Lung Cancer (NSCLC) Market
  • Reimbursement Scenario in the Non-Small Cell Lung Cancer (NSCLC) Market
  • In-Market and Pipeline Drugs
     

This report also provides a detailed analysis of the current Non-Small Cell Lung Cancer (NSCLC) marketed drugs and late-stage pipeline drugs.

In-Market Non-Small Cell Lung Cancer (NSCLC) Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Non-Small Cell Lung Cancer (NSCLC) Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Regulatory Status
     

Key Questions Answered in this Report

Market Insights

  • How has the Non-Small Cell Lung Cancer (NSCLC) market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2021 and how are they expected to be in 2032?
  • What was the country-wise size of the Non-Small Cell Lung Cancer (NSCLC) market across the seven major markets in 2021 and how will it look like in 2032?
  • What is the growth rate of the Non-Small Cell Lung Cancer (NSCLC) market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the Non-Small Cell Lung Cancer (NSCLC) market?
     

Epidemiology Insights

  • What is the size of the Non-Small Cell Lung Cancer (NSCLC) patient pool (2017-2021) across the seven major markets?
  • What would be the forecasted patient pool (2022-2032) of Non-Small Cell Lung Cancer (NSCLC) across the seven major markets?
  • What are the key factors driving the epidemiological trend of Non-Small Cell Lung Cancer (NSCLC)?
  • What will be the growth rate of Non-Small Cell Lung Cancer (NSCLC) patients across the seven major markets?
     

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed Non-Small Cell Lung Cancer (NSCLC) drugs and what are their market performance?
  • What are the key pipeline Non-Small Cell Lung Cancer (NSCLC) drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed Non-Small Cell Lung Cancer (NSCLC) drugs and what are their efficacies?
  • How safe are the late-stage pipeline Non-Small Cell Lung Cancer (NSCLC) drugs and what are their efficacies?
  • What are the current treatment guidelines for Non-Small Cell Lung Cancer (NSCLC) drugs across the seven major markets?
  • Who are the key companies in the Non-Small Cell Lung Cancer (NSCLC) market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Non-Small Cell Lung Cancer (NSCLC) market?

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Non-Small Cell Lung Cancer (NSCLC) - Introduction
4.1 Overview
4.2 Epidemiology (2017-2021) and Forecast (2022-2032)
4.3 Market Overview (2017-2021) and Forecast (2022-2032)
4.4 Competitive Intelligence

5 Non-Small Cell Lung Cancer (NSCLC) - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Non-Small Cell Lung Cancer (NSCLC) - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2021)
7.2.2 Epidemiology Forecast (2022-2032)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2021)
7.3.2 Epidemiology Forecast (2022-2032)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2021)
7.4.2 Epidemiology Forecast (2022-2032)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2021)
7.5.2 Epidemiology Forecast (2022-2032)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2021)
7.6.2 Epidemiology Forecast (2022-2032)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2021)
7.7.2 Epidemiology Forecast (2022-2032)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2021)
7.8.2 Epidemiology Forecast (2022-2032)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2021)
7.9.2 Epidemiology Forecast (2022-2032)

8 Non-Small Cell Lung Cancer (NSCLC) - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Non-Small Cell Lung Cancer (NSCLC) Guidelines, Management and Treatment
8.2 Non-Small Cell Lung Cancer (NSCLC) Treatment Algorithm

9 Non-Small Cell Lung Cancer (NSCLC) - Unmet Needs

10 Non-Small Cell Lung Cancer (NSCLC) - Key Endpoints of Treatment

11 Non-Small Cell Lung Cancer (NSCLC) - Marketed Products
11.1 List of Non-Small Cell Lung Cancer (NSCLC) Marketed Drugs Across the Top 7 Markets
11.1.1    Rozlytrek (Entrectinib) - Hoffmann-La Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2    Imfinzi (Durvalumab) - AstraZeneca
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3    Opdivo (Nivolumab) - Bristol-Myers Squibb
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4    Keytruda (Pembrolizumab) - Merck
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5    Vizimpro (Dacomitinib) - Pfizer
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report

12 Non-Small Cell Lung Cancer (NSCLC) - Pipeline Drugs
12.1 List of Non-Small Cell Lung Cancer (NSCLC) Pipeline Drugs Across the Top 7 Markets
12.1.1 EGF816 (Nazartinib) - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Telisotuzumab Vedotin - AbbVie
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SAR408701 (Tusamitamab Ravtansine) - Sanofi
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ACZ885 (Canakinumab) - Novartis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BAVENCIO (Avelumab) - Merck/Pfizer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report

13. Non-Small Cell Lung Cancer (NSCLC) - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Non-Small Cell Lung Cancer (NSCLC) - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.2.1.1 Market Size (2017-2021)
14.2.1.2 Market Forecast (2022-2032)
14.2.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2021)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.3.1.1 Market Size (2017-2021)
14.3.1.2 Market Forecast (2022-2032)
14.3.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2021)
14.3.2.2 Market Forecast by Therapies (2022-2032)
14.3.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.4.1.1 Market Size (2017-2021)
14.4.1.2 Market Forecast (2022-2032)
14.4.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2021)
14.4.2.2 Market Forecast by Therapies (2022-2032)
14.4.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.5.1.1 Market Size (2017-2021)
14.5.1.2 Market Forecast (2022-2032)
14.5.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2021)
14.5.2.2 Market Forecast by Therapies (2022-2032)
14.5.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.6.1.1 Market Size (2017-2021)
14.6.1.2 Market Forecast (2022-2032)
14.6.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2021)
14.6.2.2 Market Forecast by Therapies (2022-2032)
14.6.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.7.1.1 Market Size (2017-2021)
14.7.1.2 Market Forecast (2022-2032)
14.7.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2021)
14.7.2.2 Market Forecast by Therapies (2022-2032)
14.7.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.8.1.1 Market Size (2017-2021)
14.8.1.2 Market Forecast (2022-2032)
14.8.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2021)
14.8.2.2 Market Forecast by Therapies (2022-2032)
14.8.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Non-Small Cell Lung Cancer (NSCLC)  - Market Size
14.9.1.1 Market Size (2017-2021)
14.9.1.2 Market Forecast (2022-2032)
14.9.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2021)
14.9.2.2 Market Forecast by Therapies (2022-2032)
14.9.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview

15 Non-Small Cell Lung Cancer (NSCLC) - Recent Events and Inputs From Key Opinion Leaders

16 Non-Small Cell Lung Cancer (NSCLC) Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix


Note: We value your privacy and will never rent or sell your email address. Privacy policy

Need more help?

  •   Speak to our experienced analysts for insights on the current market scenarios.
  •   Include additional segments and countries to customize the report as per your requirement.
  •   Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  •   For further assistance, please connect with our analysts.

Purchase Options




$ 4499

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )


Drop us an email at

sales@imarcgroup.com

Social Links

4